Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results.

October 6, 2023 Immune Biosolutions is pleased to share the most recent findings from our second Phase 1/2 clinical trial (NCT05303376). This study focused on evaluating the safety and efficacy of repeated doses of IBIO123 in treating severe COVID-19 cases among recently hospitalized patients. Article available in preprint: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4593223

The release as fetched from its publisher. immunebiosolutions.com ↗